3-(3,4-Dichlorophenyl)prop-2-enoic acid → 4-[(E)-3-(3,4-Dichloro-phenyl)-acryloyl]-1-(2-pyrrolidin-1-yl-ethyl)-piperazin-2-one
반응식
C(O[C:6]([N:8]1[CH2:13][CH2:12][N:11]([CH2:14][CH2:15][N:16]2[CH2:20][CH2:19][CH2:18][CH2:17]2)[C:10](=[O:21])[CH2:9]1)=[O:7])(C)(C)C.[Cl:22][C:23]1[CH:24]=[C:25]([CH:31]=[CH:32][C:33]=1[Cl:34])[CH:26]=[CH:27]C(O)=O>>[Cl:22][C:23]1[CH:24]=[C:25](/[CH:26]=[CH:27]/[C:6]([N:8]2[CH2:13][CH2:12][N:11]([CH2:14][CH2:15][N:16]3[CH2:17][CH2:18][CH2:19][CH2:20]3)[C:10](=[O:21])[CH2:9]2)=[O:7])[CH:31]=[CH:32][C:33]=1[Cl:34]참가 물질
3
실험 절차
The title compound was prepared in analogy to example 6 starting from 3-oxo-4-(2-pyrrolidin-1-yl-ethyl)-piperazine-1-carboxylic acid tert-butyl ester (intermediate 6) and 3,4-dichlorocinnamic acid. MS (ISP)=396.4 (M+H)+.
출처 및 근거
- ORD 기록
- ord-cd49b29c101741bc91e602ad1f7c1e33
- 출처 데이터셋
- uspto-grants-2011_11
- DOI